Core candidate neurochemical and imaging biomarkers of Alzheimer’s disease

@article{Hampel2008CoreCN,
  title={Core candidate neurochemical and imaging biomarkers of Alzheimer’s disease},
  author={H. Hampel and K. B{\"u}rger and S. Teipel and A. Bokde and K. Blennow},
  journal={Alzheimer's & Dementia},
  year={2008},
  volume={4},
  pages={38-48}
}
In the earliest clinical stages of Alzheimer's disease (AD) when symptoms are mild, clinical diagnosis can be difficult. AD pathology most likely precedes symptoms. Biomarkers can serve as early diagnostic indicators or as markers of preclinical pathologic change. Candidate biomarkers derived from structural and functional neuroimaging and those measured in cerebrospinal fluid (CSF) and plasma show the greatest promise. Unbiased exploratory approaches, eg, proteomics or cortical thickness… Expand
464 Citations
Current application of neurochemical biomarkers in the prediction and differential diagnosis of Alzheimer’s disease and other neurodegenerative dementias
  • 29
Biological Marker Candidates of Alzheimer's Disease in Blood, Plasma, and Serum
  • 127
Use of Biomarkers in Clinical Trials of Alzheimer Disease
  • 11
Using biomarkers to improve detection of Alzheimer's disease.
  • 29
Fluid and imaging biomarkers for Alzheimer's disease: Where we stand and where to head to
  • 17
  • Highly Influenced
Biomarkers for Alzheimer's disease therapeutic trials
  • 124
  • PDF
Quantitative structural MRI for early detection of Alzheimer’s disease
  • 50
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 113 REFERENCES
CSF markers for incipient Alzheimer's disease
  • 1,144
Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage alzheimer’s disease
  • 426
Neuroanatomy of Down Syndrome in vivo: A Model of Preclinical Alzheimer’s Disease
  • 116
  • PDF
Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment
  • 1,284
...
1
2
3
4
5
...